RU2003122348A - Скрининг антагонистов рецепторов лейкоцитов человека - Google Patents
Скрининг антагонистов рецепторов лейкоцитов человека Download PDFInfo
- Publication number
- RU2003122348A RU2003122348A RU2003122348/15A RU2003122348A RU2003122348A RU 2003122348 A RU2003122348 A RU 2003122348A RU 2003122348/15 A RU2003122348/15 A RU 2003122348/15A RU 2003122348 A RU2003122348 A RU 2003122348A RU 2003122348 A RU2003122348 A RU 2003122348A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- ligand
- receptors
- internalization
- induced
- Prior art date
Links
- 238000012216 screening Methods 0.000 title claims 5
- 210000000265 leukocyte Anatomy 0.000 title claims 4
- 238000000034 method Methods 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- 102000005962 receptors Human genes 0.000 claims 10
- 239000003446 ligand Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 230000001629 suppression Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000004957 immunoregulator effect Effects 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 238000000684 flow cytometry Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000002372 labelling Methods 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000033300 receptor internalization Effects 0.000 claims 2
- -1 CD86 Proteins 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims 1
- 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims 1
- 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000004624 confocal microscopy Methods 0.000 claims 1
- 108091008034 costimulatory receptors Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 102000034287 fluorescent proteins Human genes 0.000 claims 1
- 108091006047 fluorescent proteins Proteins 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000007431 microscopic evaluation Methods 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (20)
1. Способ скрининга соединений на их способность ингибировать каскады лиганд-индуцированной костимуляторной интернализации рецепторов в иммунокомпетентных клетках человека, отличающийся тем, что указанные иммунокомпетентные клетки инкубируют в условиях, способных индуцировать костимуляторную интернализацию рецепторов в присутствии, по меньшей мере, одного тестируемого соединения, и выявляют супрессии лиганд-индуцированной костимуляторной интернализации рецепторов.
2. Способ по п.1, где указанные иммунокомпетентные клетки представляют собой лейкоциты.
3. Способ по п.2, где указанные лейкоциты представляют собой лимфоциты.
4. Способ по п.3, где указанные лимфоциты представляют собой Т-клетки.
5. Способ по п.4, где указанные T-клетки представляют собой клетки Jurkat.
6. Способ по п.2, где указанные лейкоциты представляют собой антиген-презинтирующие клетки.
7. Способ по п.6, где указанные антиген-презинтирующие клетки являются В-клетками.
8. Способ по любому из пп.1-7, где указанные условия заключают в себе культивирование иммунокомпетентных клеток с овариальными клетками китайского хомячка (CHO), трансфицированных ДНК, которая кодирует, по меньшей мере, один лиганд человека.
9. Способ по п.8, где клетки CHO трансфицированы ДНК, кодирующей, по меньшей мере, один лиганд человека или рецептор, выбранный из группы, содержащей ICAM, CD54(LPA3), CD40, CD80, CD86, CD154(CD40L).
10. Способ по одному из пп.1-9, где тестируемое соединение представляет собой соединение с низкой молекулярной массой.
11. Способ по п.10, где тестируемое соединение имеет молекулярную массу примерно до 500.
12. Способ по любому из пп.1-11, где указанное выявление супрессии проводят проточной цитометрией или конфокальным микроскопическим анализом клеток.
13. Способ по одному из пп.1-12, автоматизированный для проведения скрининга с высоким содержанием (HCS) или среднепроизводительного скрининга (MTS).
14. Способ по одному из пп.1-13, где указанные каскады выбраны из группы лиганд-рецепторных пар, включающих в себя CD40/CD154(CD40L), CD2/LFA3, CD28/CD80, CD86 и CD11/ICAM.
15. Набор для использования при скрининге соединений на их способность ингибировать лиганд-индуцированную костимулированную интернализацию рецепторов в иммунокомпетентных клетках человека, содержащий средство для выращивания иммунокомпетентных клеток человека, средство для индуцирования костимуляторной интернализации рецепторов, средство для инкубирования иммунокомпетентных клеток человека, по меньшей мере, с одним тестируемым соединением, средство для мечения рецепторов, и средство для выявления супрессии лиганд-индуцированной костимуляторной интернализации рецепторов.
16. Набор по п.15, где конъюгат с изотопом или флуоресцентным белком применяют для мечения рецепторов.
17. Набор по п.15 или 16, где проточную цитометрию или конфокальную микроскопию применяют для выявления супрессии лиганд-индуцированной костимуляторной интернализации рецепторов.
18. Иммунорегуляторное лекарственное средство, способное блокировать отрицательную модуляцию лиганд-индуцированного рецептора, таким образом, предупреждая лиганд-индуцированную интернализацию рецепторов.
19. Иммунорегуляторное лирующее лекарственное средство по п.18, представляющее собой соединение с низкой молекулярной массой.
20. Иммунорегуляторное унорегул лекарственное средство по п.18 или 19, представляющее собой соединение с молекулярной массой примерно до 500.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0004781A SE0004781D0 (sv) | 2000-12-22 | 2000-12-22 | A screening assay for antagonists of human leukocyte receptors |
| SE0004781-1 | 2000-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003122348A true RU2003122348A (ru) | 2005-01-27 |
Family
ID=20282361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003122348/15A RU2003122348A (ru) | 2000-12-22 | 2001-12-20 | Скрининг антагонистов рецепторов лейкоцитов человека |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040106160A1 (ru) |
| EP (1) | EP1344063A1 (ru) |
| JP (1) | JP2004516037A (ru) |
| CN (1) | CN1481504A (ru) |
| CA (1) | CA2436777A1 (ru) |
| NO (1) | NO20032458L (ru) |
| RU (1) | RU2003122348A (ru) |
| SE (1) | SE0004781D0 (ru) |
| WO (1) | WO2002052268A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201104950D0 (en) * | 2011-03-24 | 2011-05-11 | Univ Birmingham | Immune assay |
| CN104977237B (zh) * | 2015-07-01 | 2018-02-23 | 北京理工大学 | 一种原位检测单个活细胞内细胞器中co2生成速率的方法 |
| CN113981031B (zh) * | 2021-11-01 | 2024-12-06 | 山西中医药大学 | 一种新型t细胞功能检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4535893A (en) * | 1992-06-15 | 1994-01-04 | Regents Of The University Of California, The | Screening assay for the identification of immunosuppressive drugs |
| WO1994014065A1 (en) * | 1992-12-14 | 1994-06-23 | Dana-Farber Cancer Institute, Inc. | Methods for identifying and using immunosuppressant compounds |
| DK1095277T3 (da) * | 1998-07-13 | 2003-04-22 | Cellomics Inc | System til cellebaseret screening |
| DE69920757T2 (de) * | 1998-12-28 | 2005-12-15 | 4 AZA Bioscience N.V. | Immunosuppressive wirkungen von pteridinderivaten |
| FR2788602B1 (fr) * | 1999-01-20 | 2002-06-07 | Inst Nat Sante Rech Med | Procede de criblage utile pour identifier des ligands potentiels pour un recepteur capable de s'internaliser |
| US6642249B2 (en) * | 2001-07-04 | 2003-11-04 | Active Biotech Ab | Immunomodulating compounds |
-
2000
- 2000-12-22 SE SE0004781A patent/SE0004781D0/xx unknown
-
2001
- 2001-12-20 EP EP01272418A patent/EP1344063A1/en not_active Withdrawn
- 2001-12-20 RU RU2003122348/15A patent/RU2003122348A/ru not_active Application Discontinuation
- 2001-12-20 WO PCT/SE2001/002841 patent/WO2002052268A1/en not_active Ceased
- 2001-12-20 JP JP2002553116A patent/JP2004516037A/ja not_active Withdrawn
- 2001-12-20 CN CNA01821066XA patent/CN1481504A/zh active Pending
- 2001-12-20 US US10/432,726 patent/US20040106160A1/en not_active Abandoned
- 2001-12-20 CA CA002436777A patent/CA2436777A1/en not_active Abandoned
-
2003
- 2003-05-30 NO NO20032458A patent/NO20032458L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1344063A1 (en) | 2003-09-17 |
| NO20032458D0 (no) | 2003-05-30 |
| CA2436777A1 (en) | 2002-07-04 |
| NO20032458L (no) | 2003-06-18 |
| SE0004781D0 (sv) | 2000-12-22 |
| CN1481504A (zh) | 2004-03-10 |
| US20040106160A1 (en) | 2004-06-03 |
| WO2002052268A1 (en) | 2002-07-04 |
| JP2004516037A (ja) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matile et al. | Plasmodium falciparum malaria parasite cultures and their use in immunology | |
| Van Oers et al. | Expression and release of CD27 in human B-cell malignancies | |
| Slifka et al. | Activated and memory CD8+ T cells can be distinguished by their cytokine profiles and phenotypic markers | |
| Munk Pedersen et al. | Microenvironmental interactions and survival of CLL B-cells | |
| Vremec et al. | CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen | |
| Cerwenka et al. | Fas-and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-β 1 | |
| Sprent et al. | T cell memory | |
| Blakely et al. | Resistance of cloned cytotoxic T lymphocytes to cell-mediated cytotoxicity. | |
| Ardavin et al. | Cell surface marker analysis of mouse thymic dendritic cells | |
| González-Cuadrado et al. | Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells | |
| Eberlein et al. | Multiple layers of CD80/86-dependent costimulatory activity regulate primary, memory, and secondary lymphocytic choriomeningitis virus-specific T cell immunity | |
| KORNGOLD et al. | Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation | |
| Gordon et al. | Capacity of B‐lymphocytic lines of diverse tumor origin to produce and respond to B‐cell growth factors: A progression model for B‐cell lymphomagenesis | |
| CA2063578A1 (en) | T-lymphocyte progenitor cell assay | |
| Schwartz et al. | Histamine inhibition of the in vitro induction of cytotoxic T-cell responses | |
| Remington et al. | The RNA of Toxoplasma gondii | |
| Martin et al. | HLA-DR, ICAM-1, CD40, CD40L, and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex vivo | |
| RU2003122348A (ru) | Скрининг антагонистов рецепторов лейкоцитов человека | |
| Park et al. | Origins of the first HLA specificities | |
| Sheasley-O’Neill et al. | Dendritic cell immunization route determines integrin expression and lymphoid and nonlymphoid tissue distribution of CD8 T cells | |
| Chen et al. | RGD-containing peptides trigger apoptosis in glomerular mesangial cells of adult human kidneys | |
| Van Deusen et al. | CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses | |
| Takahashi et al. | Morphological interactions of interdigitating dendritic cells with B and T cells in human mesenteric lymph nodes | |
| Francis et al. | Production of a lymphokine (macrophage activating factor) by salmon (Salmo salar) leucocytes stimulated with outer membrane protein antigens of Aeromonas salmonicida | |
| Sen-Majumdar et al. | Differentiation of CD3-4-8-thymocytes in short-term thymic stromal cell culture. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060405 |